| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
TORRENT PHARMACEUTICALS LTD. (BSE: 500420)
500420 Technical Analysis
5
| As on 3rd May 2024 500420 SHARE Price closed @ 2732.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2175.12 & Strong Buy for SHORT-TERM with Stoploss of 2619.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
500420SHARE Price
| Open | 2683.00 | Change | Price | % |
| High | 2782.00 | 1 Day | 58.80 | 2.20 |
| Low | 2683.00 | 1 Week | 42.15 | 1.57 |
| Close | 2732.60 | 1 Month | 143.70 | 5.55 |
| Volume | 12576 | 1 Year | 1078.60 | 65.21 |
| 52 Week High 2782.00 | 52 Week Low 1599.00 | ||||
BSE INDIA Most Active Stocks
| 532822 | 13.19 | -0.23% |
| 532648 | 24.96 | -1.89% |
| 532775 | 1.72 | -2.27% |
| 533122 | 9.31 | 0.98% |
| 512149 | 1.05 | 5.00% |
| 500106 | 52.51 | 4.81% |
| 533098 | 99.23 | 1.24% |
| 517001 | 0.09 | 12.50% |
| 532022 | 12.99 | 7.62% |
| 532532 | 19.89 | -2.45% |
BSE INDIA Top Gainers Stocks
BSE INDIA Top Losers Stocks
| 500420 Daily Charts |
500420 Intraday Charts |
Whats New @ Bazaartrend |
500420 Free Analysis |
|
|
500420 Important Levels Intraday
| RESISTANCE | 2923.37 |
| RESISTANCE | 2862.19 |
| RESISTANCE | 2824.37 |
| RESISTANCE | 2786.56 |
| SUPPORT | 2678.65 |
| SUPPORT | 2640.83 |
| SUPPORT | 2603.01 |
| SUPPORT | 2541.83 |
500420 Target May 2024
| 4th UP Target | 3093.44 |
| 3rd UP Target | 2948.15 |
| 2nd UP Target | 2858.34 |
| 1st UP Target | 2768.53 |
| 1st DOWN Target | 2512.27 |
| 2nd DOWN Target | 2422.46 |
| 3rd DOWN Target | 2332.65 |
| 4th DOWN Target | 2187.36 |
500420 Weekly Target
| 4th UP Target | 3062.84 |
| 3rd UP Target | 2943.41 |
| 2nd UP Target | 2869.59 |
| 1st UP Target | 2795.77 |
| 1st DOWN Target | 2585.13 |
| 2nd DOWN Target | 2511.31 |
| 3rd DOWN Target | 2437.49 |
| 4th DOWN Target | 2318.06 |
500420 Target2024
| 4th UP Target | 3969.45 |
| 3rd UP Target | 3435.65 |
| 2nd UP Target | 3105.7 |
| 1st UP Target | 2775.74 |
| 1st DOWN Target | 1834.26 |
| 2nd DOWN Target | 1504.3 |
| 3rd DOWN Target | 1174.35 |
| 4th DOWN Target | 640.55 |
TORRENT PHARMACEUTICALS LTD. ( BSE INDIA Symbol : 500420 )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
500420 Business Profile
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology, pediatric, wound care, and nutraceuticals. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Private Limited. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service